Figure 4
From: Clinicopathological significance of the CRTC3–MAML2 fusion transcript in mucoepidermoid carcinoma
Disease-free (a) and overall (b) survival of patients with CRTC1–MAML2, CRTC3–MAML2, and no detectable gene fusion. Five-year disease-free survival for patients with CRTC3–MAML2, CRTC1–MAML2, and fusion-negative tumors is 100, 76, and 52%, respectively. Five-year overall survival for patients with CRTC3–MAML2, CRTC1–MAML2, and fusion-negative tumors is 100, 100, and 53%, respectively.
